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During the last decade, RNA interference (RNAi) has become an important 
tool to investigate the function of genes and the gene-gene interaction 
between them. By adding double stranded RNA (dsRNA) constructs, the 
RNAi pathway induces downregulation of the expression of a gene [1]. This 
is done by administering dsRNAs with sequence homology against the 
target gene. The dsRNAs inflict a cascade of reactions ending in the 
destruction of the messenger RNA (mRNA) originating from the target 
gene, and as a consequence the protein is not formed. By studying the 
phenotype induced by downregulation of the mRNA, the function of the 
chosen gene is elucidated. Unfortunately, RNAi may also have collateral 
effects, of which the so called off-targets are the most important. Off-target 
effects can occur because of the presence of sequence similarity between the 
target genes and other, genes.  
RNAiSelect;	a	novel	bioinformatics	tool	that	profiles	off‐targets	
With time, knowledge grew about how RNAi works and what the 
limitations are in using them for experiments [2]. One of these limitations is 
that off-targets may occur when an RNAi molecule has similarity to other 
regions on the genome than its intended target [3]. Bioinformatics plays a 
key role in circumventing these off-targets by analysing the sequence of the 
RNAi molecule and reporting about the uniqueness amongst genes [4,5,6].  
Still, one important property of RNAi was ignored by the current available 
tools: The RNAi machinery can not only target mature RNA sequences but 
can also target intron containing pre-messenger RNA and other nuclear 
located RNAs [7,8,9]. This has major consequences for the generality of the 
already existing bioinformatics tools, as these are only considering mature 
messenger RNA (mRNA) present in the cytoplasm. The knowledge that the 
RNAi machinery can also have a nuclear localization, indicates that there 
are many more sequences that can be the target of regulatory breakdown. 
Our tool “RNAiSelect” (chapter 2) responds to these observations by 
allowing a much more thorough analysis including the complete genome to 
find off-targets. RNAiSelect is based on a novel algorithm that requires only 
seconds to complete a comprehensive search of 21-nt against the complete 
genome while allowing up to 3 mismatches. By analysing the complete 





(i.e. miRNAs) or unknown regions of the genome. This approach certainly 
has ample false-positive hits caused by sequences that do have similarity to 
the RNAi molecule under investigation, but do not inflict a real biological 
effect. However, it is important to realize that the purpose of 
RNAiSelect is not to identify off-targets per se, but to select the best 
RNAi molecule candidates amongst the many that are possible. By 
analysing all candidate siRNAs that may be created for a particular target 
gene, the ones with the least number of predicted potential off-targets will 
be the most preferable ones and from which the most suitable according to 
efficiency properties may be chosen. In addition, the number of mismatches 
against predicted potential off-targets as well as the type of mismatch is 
considered resulting in a general score that also aids in choosing the best 
siRNA with the least number of potential off-targets. 
We have validated our approach using publically available micro-arrays. By 
analysing the off-target profiles of the used dsRNAs and after comparing the 
output with the actual regulatory differences on the arrays, we concluded 
that RNAiSelect indeed has a predictive value regarding which sequences 
can contribute to off-targets. Although the array showed numerous marginal 
expression differences considering the complete array, a significant effect 
was observed for the set of predicted off-targets. The knowledge that small 
changes at the mRNA level can have large effects on protein expression 
levels underscores the significant effect we have found in chapter 2 [10]. 
Fortunately, in our genome-wide analysis of all potential siRNA sequences 
using RNAiSelect, we have found that the majority of genes have potent 
siRNAs with relatively few predicted potential off-targets (up to 80% less 
than average). When performing a genome-wide screen using dsRNA 
molecules, RNAiSelect will be particularly useful to identify these clean 
RNAis and assists in the decision which of them are most “clean” and 
therefore most promising to proceed with. When designing a RNAi 
experiment, one can choose a single siRNA (21 nt in length) instead of a 
large dsRNA (approximately between 250 and 800 nt in length) to prevent 
as many potential off-targets as possible. In addition, the outcome 
(especially micro-array data) of already performed RNAi experiments can 
now be re-evaluated using RNAiSelect and it can be checked whether 







It is currently not possible to predict with a high level of accuracy whether a 
specific RNAi molecule does provoke a potent on-target effect and it is also 
not possible to predict whether an off-target effect, identified by 
bioinformatic tools will indeed provoke a measurable biological effect. A 
method to circumvent the usage of bioinformatics tools is to use two 
independent and non-overlapping siRNA constructs to downregulate the 
same gene of interest. The usage of this type of controlled-experiment is 
reasonable because the assumption is that two completely different dsRNAs 
will have identical on-target effects but will have a completely different 
genome wide off-target profile. Any identical biological effect provoked by 
the distinct dsRNA constructs is considered as a bona fide on target effect.  
Unfortunately, this assumption has proven to be very wrong (chapter 3). 
Statistical analysis and our results show that within the Drosophila genome 
it is highly likely for distinct 21 nt sequences derived from the same gene to 
have closely mapped sequence similarity elsewhere on the genome. In other 
words, if one slices a Drosophila gene in pieces of 21-nt and  a sequence 
similarity analysis is performed, many of the individual 21-nt pieces will 
find homology within the same ‘other’ Drosophila gene (i.e. potential off-
target gene). Indeed, our results using actual genome data show that 
most genes have many of these sequences that map to the same 
potential off-target. We therefore concluded that an identical biological 
effect induced by randomly choosing distinct dsRNAs derived from one 
gene is not per definition a bona fide on-target effect. Moreover, our 
results show that even when 3 or more distinct dsRNAs are used, there is 
still a significant possibility of overlapping off-targets which means that 
“blindly” picking dsRNA constructs is almost never suffice to counter off-
target effects. 
Despite this knowledge, the use of a double controlled RNAi experiment is 
appealing as it may indeed prevent many false observations. RNAiSelect 
(presented in chapter 3) is useful in finding the best predicted siRNA 
candidate combinations that have most likely no shared off-targets based on 
sequence similarity. In summary, we present a method to identify 2 distinct 
dsRNAs from a gene of choice that do not show any potential off-target 





off-target overlap analysis. This tool is freely available at 
http://www.rnaiselect.info/dsrna and may be used by the Drosophila 




The procedure of using RNAi in researching a human disease model in 
Drosophila has proven to be very useful to unravel the mechanisms behind 
the disease [11]. RNAiSelect has been used in chapter 4 to generate clean 
and specific dsRNAs to model the human disease PKAN (Pantothenate 
kinase–associated neurodegeneration) in Drosophila. PKAN is a rare 
neuronal disease caused by a mutation in the human PANK2 gene. 
PANK2 is evolutionary conserved amongst many species and is essential in 
the biochemical pathway that converts vitamin B5 into Coenzyme A (CoA) 
[12]. Drosophila has proven to be particularly suitable as a model for 
PKAN, as it shares many characteristics that are reported in human PKAN 
patients carrying a mutation in PANK2. These phenotypes comprise 
increased loss of locomotor function, neurodegeneration, and a decreased 
lifespan.  
With RNAi, a cell based PKAN Drosophila model (S2) was created. A 
biochemically measurable effect of this knock-down mutant cell line is the 
severely decreased levels of CoA. In addition, a phenotypical effect is 
measured through decreased cell-count in time. By adding the chemical 
substrate pantethine to the growth medium, CoA levels and cell numbers 
were restored comparable to wild type S2 cells. Thus our research suggests 
that an alternative route may exist leading from pantethine to CoA, 
independent from pantothenate kinase. This hypothesis is further supported 
by our findings that any residual dPank/fbl kinase activity does not on itself 
contribute to the phosphotransferase conversion of Pantethine, because (1) 
western blotting demonstrated the nearly complete knock-down of 
dPank/fbl and (2) the addition of increasing concentrations of vitamin B5 
did not have any significant effect on the mutant phenotype. 
Pantethine has also been administered to Drosophila fly mutants, which 
rescues all tested aspects of their neurodegenerative phenotype and 




model for PKAN, pantethine also works protective. Together our results 
show that a well-controlled RNAi experiment in Drosophila S2 cells leads 
to the identification of a lead compound, that may be at the base of a 
possible treatment for a so far non-treatable disease.  
Identifying	miRNA	targets	in	human	cells	to	understand	Hodgkin	
Lymphoma	
In addition to the possibility of our algorithm to search for full length 
sequence similarities, short 6-nt ‘seed’ sequences that can result in possible 
miRNA-like effects can be searched for. The latter is also useful for 
identifying or confirming naturally occurring miRNA targets that regulate 
endogenous genes. This is particularly interesting for research concerning 
the role of miRNAs in developmental regulation, but also to study the effect 
of malfunctioning miRNAs as they occur in several cancerous diseases like 
Hodgkin Lymphoma (HL; a cancer originating from leucocytes).  
Chapter 5 describes a high-throughput approach to identify endogenous 
miRNA targets of untreated human cells in which specific miRNAs are 
upregulated. The approach uses a combination of wet experiments (in 
vitro/vivo studies) and RNAiSelect (in silico) capabilities to find sequence 
similarities. While other methods have been established to find miRNA 
targets, none of them can be done in a wild type background because these 
published methods make use of cells that overexpress synthetic miRNAs 
and flag-tagged miRNA related proteins which require a significant 
modulation of the cells [13,14,15,16,17]. These approaches clearly influence 
the physiological state of the cells under investigation and will affect the 
outcome of the experiments. This underscores the need for a better system. 
Our high throughput approach (as described in chapter 5) is not altering 
physiological conditions and is accomplished by using antibodies against 
Argonaute (Ago2; which is the catalytic component of the RISC complex 
that binds and cleaves targeted mRNAs by complementary binding with the 
miRNA seed region) in combination with immuno-precipitation of this 
RISC complex. The precipitated complex contains mRNAs that were bound 
to RISC and are therefore candidate miRNA targets. Using this method, 
miRNA targets bound to Ago2 can be isolated from untreated and 






A proof of principle has been performed by using 2 different HL cell lines 
that have several characteristic miRNAs upregulated (miR-17/20/93/106).  
First, RISC from untreated HL cells was isolated and attached mRNAs were 
isolated, sequenced and identified. Next, the HL cell lines have been 
transfected with anti-miRNAs (i.e. anti-miR-17) and again pools of mRNAs 
that were attached to Ago2 have been isolated. By cross-referencing both 
pools, mRNAs that are bound to RISC in the unaltered cells but not in 
transfected cells could be isolated and were candidates for being actual 
targets of the miRNAs under investigation.  
Although this pool is large and contains many false positives due to non-
specific or non-related binding of mRNAs to RISC, it is a perfect start for 
RNAiSelect to condense the list of candidate genes to a validated list based 
on seed complementarity to the miRNAs under inverstigation. By using 
RNAiSelect, a list of mRNAs containing highly significant enrichment of 
seed-sequences against the miRNAs under investigation has been isolated 
from the large pool of mRNA that were found in the Ago2 immune-
precipitate. Because these mRNAs are both found in RISC and have 
multiple occurrences of the seed sequences against miRNAs that are known 
to be highly active, it is very likely for them to be actual targets. Indeed, by 
using luciferase assays against 8 chosen genes from the isolated mRNA set 
predicted to be downregulated by miRNA-17, all of them are confirmed to 
be upregulated upon miRNA-17 inhibition. Notably, 2 genes have also been 
assayed using the same method, which showed significant enrichment in the 
Ago complex, but appeared to lack the seed region of miRNA-17 after 
analyzing with RNAiSelect. Upon miRNA-17 inhibition, the correlation 
with this miRNA could not be confirmed consisting with the lacking seed 
region. This observation demonstrates that initial large pools of mRNAs 
could effectively be reduced with RNAiSelect by reducing false positives 
and therefore provides the necessary sensitivity of the novel high-
throughput approach to identify miRNA targets. 
This thesis has also given new insights into how miRNA-mRNA 
interactions occur. Studies from the Bartel group have shown that 8-mer 
seed sequences show a higher and more reliable occurrence of interaction, 
suggesting a preference for these 8-mer interactions [18]. Our results 
however show that although 8-mer sites in 3’-UTR regions definitely are 
good indicators to identify miRNA-specific targets, they are not obligatory 




family were confirmed with the luciferase assay, but did not contain 8-mer 
sites as opposed to the 6-mers. 
Summarizing	conclusion	
 
Gene expression regulation by RNAs is part of a complex machinery for 
which recently most has been unraveled. Roughly this topic can be divided 
in endogenous RNA regulation and exogenous RNAi research and examples 
of both of them have been under investigation and discussed in detail in this 
thesis. First bioinformatics tools were designed to be able to evaluate results 
obtained with manipulating regulation by RNA (chapter 2 and 3) and 
subsequently these tools were implemented in ‘wet’ experiments (chapter 4 
and 5). For exogenous siRNAs or derivatives thereof, novel methods have 
been devised that aid in designing clean RNAi experiments to  identify a 
lead compound suitable to develop a future therapy for a so far non-curable 
disease. For the endogenous regulation, a novel method has been presented 
to deduce natural miRNA targets in order to interpret and further direct 
‘wet’s experiments highly efficiently. The results presented in this thesis 
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